enVVeno Medical Files Prospectus To Offer And Sell Securities For Up To $100M
-SEC Filing
Read original at benzingaStocks · News reference
enVVeno Medical Says It Received FDA IDE Approval For TAVVE Pivotal Study Of enVVe Replacement Venous Valve, Enrollment Of Approximately 230 Patients Expected To Begin In H2 2026
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 31, 2026, 12:36 PM
- Checked
- Jul 31, 2026, 12:35 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
enVVeno Announces Publication Of Peer-Reviewed Health Economics Study Supporting Venous Valve Therapy; Findings May Support Future Coverage And Reimbursement Decisions
Published economic health study shows both short- and long-term cost-effectiveness of replacement venous value therapy versus standard-of-care treatments for deep venous CVI, generating compelling evidence that will be
Read original at benzingaenVVeno Medical Says Peer-Reviewed Study Projects More Than $32K In Healthcare Savings Per Patient Over Five Years From Venous Valve Replacement Therapy
Read original at benzingaenVVeno Medical Q2 EPS $(5.37) Up From $(11.55) YoY
Read original at benzinga